The effect of intravenous administration of active recombinant factor VII on postoperative bleeding in cardiac valve reoperations; A randomized clinical trial

Anesthesiology and Pain Medicine

Volumn 5, Issue 1, 2015, Pages

  Payani, Narges ^a   Foroughi, Mahnoosh ^a   Dabbagh, Ali ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Activated recombinant factor VII; Cardiac surgical procedure; Postoperative hemorrhage; Reoperation

Indexed keywords

EID: 84921968480     PISSN: 22287523     EISSN: 22287531     Source Type: Journal    
DOI: 10.5812/aapm.22846     Document Type: Article

References (62)

1. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisen-hut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for of-label indications. Ann Intern Med. 2011;154(8):529–40.
2. Brown C, Joshi B, Faraday N, Shah A, Yuh D, Rade JJ, et al. Emergency cardiac surgery in patients with acute coronary syndromes: a review of the evidence and perioperative implications of medical and mechanical therapeutics. Anesth Analg. 2011;112(4):777–99.
3. Clark KB, Kon ND, Hammon JW, Jr., MacGregor DA, Kincaid EH, Reichert MG. Factor IX complex for the treatment of severe bleeding after cardiac surgery. J Cardiovasc Pharmacol. 2013;62(1):67–71.
4. Guzzetta NA, Russell IA, Williams GD. Review of the of-label use of recombinant activated factor VII in pediatric cardiac surgery patients. Anesth Analg. 2012;115(2):364–78.
5. Levy JH, Sniecinski RM. Prohemostatic treatment in cardiac surgery. Semin Thromb Hemost. 2012;38(3):237–43.
6. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding--a European perspective. Crit Care. 2006;10(4):R120.
7. Spinella PC, Perkins JG, McLaughlin DF, Niles SE, Grathwohl KW, Beekley AC, et al. The efect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma. 2008;64(2):286–93.
8. Dabbagh A, Rajaei S, Bahadori Monfared A, Keramatinia AA, Omidi K. Cardiopulmonary Bypass, Infammation and How to Defy it: Focus on Pharmacological Interventions. Iran J Pharm Res. 2012;11(3):705–14.
9. Dabbagh A, Rajaei S, Shamsolahrar MH. The efect of intravenous magnesium sulfate on acute postoperative bleeding in elective coronary artery bypass surgery. J Perianesth Nurs. 2010;25(5):290–5.
10. Berkhof FF, Eikenboom JC. Efcacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis. Transfusion. 2009;49(3):570–7.
11. Barnard J, Millner R. A review of topical hemostatic agents for use in cardiac surgery. Ann Thorac Surg. 2009;88(4):1377–83.
12. Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, et al. Coronary artery bypass grafting after aprotinin: are we doing better? J Thorac Cardiovasc Surg. 2013;145(1):243–8.
13. Biancari F, Mikkola R, Heikkinen J, Lahtinen J, Airaksinen KE, Juvonen T. Estimating the risk of complications related to re-exploration for bleeding after adult cardiac surgery: a systematic review and meta-analysis. Eur J Cardiothorac Surg. 2012;41(1):50–5.
14. Lee GC, Kicza AM, Liu KY, Nyman CB, Kaufman RM, Body SC. Does rotational thromboelastometry (ROTEM) improve prediction of bleeding after cardiac surgery? Anesth Analg. 2012;115(3):499–506.
15. Pasquali SK, Li JS, He X, Jacobs ML, O'Brien SM, Hall M, et al. Comparative analysis of antifbrinolytic medications in pediatric heart surgery. J Thorac Cardiovasc Surg. 2012;143(3):550–7.
16. Vernick WJ, Woo JY. Anesthetic considerations during minimally invasive mitral valve surgery. Semin Cardiothorac Vasc Anesth. 2012;16(1):11–24.
17. Ho KM, Litton E. Cost-efectiveness of using recombinant activated factor VII as an of-label rescue treatment for critical bleeding requiring massive transfusion. Transfusion. 2012;52(8):1696–702.
18. Huang WY, Kruskall MS, Bauer KA, Uhl L, Shaz BH. The use of re-combinant activated factor VII in three patients with central nervous system hemorrhages associated with factor VII defciency. Transfusion. 2004;44(11):1562–6.
19. Warren OJ, Alcock EM, Choong AM, Lef DR, Van Herzeele I, Darzi AW, et al. Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery? Eur J Vasc Endovasc Surg. 2008;35(2):145–52.
20. Pychynska-Pokorska M, Pagowska-Klimek I, Krajewski W, Moll JJ. Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2011;25(6):987–94.
21. Dell'Amore A, Caroli G, Nizar A, Cassanelli N, Luciano G, Greco D, et al. Can topical application of tranexamic acid reduce blood loss in thoracic surgery? A prospective randomised double blind investigation. Heart Lung Circ. 2012;21(11):706–10.
22. Jeganathan R, Armstrong S, Al-Alao B, David T. The risk and outcomes of reoperative tricuspid valve surgery. Ann Thorac Surg. 2013;95(1):119–24.
23. Okonta KE, Edwin F, Falase B. Is recombinant activated factor VII efective in the treatment of excessive bleeding after paediatric cardiac surgery? Interact Cardiovasc Thorac Surg. 2012;15(4):690–4.
24. Uber WE, Toole JM, Stroud MR, Haney JS, Lazarchick J, Crawford FA, Jr., et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes. J Thorac Cardiovasc Surg. 2011;141(6):1469–77 e2
25. Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, et al. Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage. Stroke. 2008;39(3):850–6.
26. Yuan ZH, Jiang JK, Huang WD, Pan J, Zhu JY, Wang JZ. A meta-anal-ysis of the efcacy and safety of recombinant activated factor VII for patients with acute intracerebral hemorrhage without hemophilia. J Clin Neurosci. 2010;17(6):685–93.
27. Bauza G, Hirsch E, Burke P, Quillen K. Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy. Transfusion. 2007;47(4):749–51.
28. Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF. Use of recom-binant activated Factor VII for refractory after lung transplant bleeding as an efective strategy to restrict blood transfusion and associated complications. Transfusion. 2013;53(4):798–804.
29. Bofard KD, Choong PI, Kluger Y, Riou B, Rizoli SB, Rossaint R, et al. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage. Transfusion. 2009;49 Suppl 5:240S–7S.
30. Levi M, Peters M, Buller HR. Efcacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med. 2005;33(4):883–90.
31. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thrombo-embolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293–8.
32. Johansson PI. Of-label use of recombinant factor VIIa for treatment of haemorrhage: results from randomized clinical trials. Vox Sang. 2008;95(1):1–7.
33. Wittenstein B, Ng C, Ravn H, Goldman A. Recombinant factor VII for severe bleeding during extracorporeal membrane oxy-genation following open heart surgery. Pediatr Crit Care Med. 2005;6(4):473–6.
34. Benharash P, Bongard F, Putnam B. Use of recombinant factor VIIa for adjunctive hemorrhage control in trauma and surgical patients. Am Surg. 2005;71(9):776–80.
35. Bofard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59(1):8–15.
36. Clark AD, Gordon WC, Walker ID, Tait RC. 'Last-ditch' use of re-combinant factor VIIa in patients with massive haemorrhage is inefective. Vox Sang. 2004;86(2):120–4.
37. Duchesne JC, Mathew KA, Marr AB, Pinsky MR, Barbeau JM, McSwain NE. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly. Am Surg. 2008;74(12):1159–65.
38. Stanworth SJ, Birchall J, Doree CJ, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2007(2):CD005011.
39. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recom-binant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;3:CD005011.
40. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, My-then M, et al. Safety and efcacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation. 2009;120(1):21–7.
41. von Heymann C, Jonas S, Spies C, Wernecke KD, Ziemer S, Jans-sen D, et al. Recombinant activated factor VIIa for the treatment of bleeding in major abdominal surgery including vascular and urological surgery: a review and meta-analysis of published data. Crit Care. 2008;12(1):R14.
42. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2002;16(5):615–6.
43. von Heymann C, Redlich U, Jain U, Kastrup M, Schroeder T, Sander M, et al. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efcacy. Crit Care Med. 2005;33(10):2241–6.
44. von Heymann C, Schoenfeld H, Sander M, Ziemer S, Grubitzsch H, Spies C. Clopidogrel-related refractory bleeding after coronary artery bypass graft surgery: a rationale for the use of coagulation factor concentrates? Heart Surg Forum. 2005;8(1):E39–41.
45. Diprose P, Herbertson MJ, O'Shaughnessy D, Gill RS. Activated re-combinant factor VII after cardiopulmonary bypass reduces al-logeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study. Br J Anaesth. 2005;95(5):596–602.
46. Richardson A, Herbertson M, Gill R. The role of recombinant activated factor VII in cardiac surgery. HSR Proc Intensive Care Cardio-vasc Anesth. 2009;1(3):9–12.
47. Warren OJ, Rogers PL, Watret AL, de Wit KL, Darzi AW, Gill R, et al. Defning the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here? Pediatr Crit Care Med. 2009;10(5):572–82.
48. Hardy JF, Belisle S, Van der Linden P. Efcacy and safety of activated recombinant factor VII in cardiac surgical patients. Curr Opin Anaesthesiol. 2009;22(1):95–9.
49. Levy JH, Tanaka KA. Prohemostatic agents to prevent periopera-tive blood loss. Semin Thromb Hemost. 2008;34(5):439–44.
50. Ranucci M, Baryshnikova E, Colella D. Monitoring prohemo-static treatment in bleeding patients. Semin Thromb Hemost. 2012;38(3):282–91.
51. Ranucci M, Isgro G, Soro G, Conti D, De Tofol B. Efcacy and safety of recombinant activated factor vii in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg. 2008;143(3):296–304.
52. Roberts HR, Monroe DM, 3rd, Hofman M. Safety profle of recom-binant factor VIIa. Semin Hematol. 2004;41(1 Suppl 1):101–8.
53. Chapman AJ, Blount AL, Davis AT, Hooker RL. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardio-thorac Surg. 2011;40(6):1314–8.
54. Karkouti K, Beattie WS, Crowther MA, Callum JL, Chun R, Fremes SE, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anaesth. 2007;54(7):573–82.
55. Sattler S, Schwartz A. Does the use of recombinant factor VIIA reduce morbidity or mortality in nonhemophiliac patients? Ann Emerg Med. 2012;60(2):160–1.
56. Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs. 2002;62(15):2193–211.
57. Society of Thoracic Surgeons Blood Conservation Guideline Task F, Ferraris VA, Ferraris SP, Saha SP, Hessel E, Haan CK, et al. Peri-operative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5 Suppl):S27–86.
58. Vamvakas EC, Blajchman MA. Blood still kills: six strategies to further reduce allogeneic blood transfusion-related mortality. Transfus Med Rev. 2010;24(2):77–124.
59. Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood. 2009;113(15):3406–17.
60. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion. 2009;49(12):2743–58.
61. Vamvakas EC. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice. Transfusion. 2013;53(4):888–901.
62. Tayebi Meybodi K, Taghvaei M, Derakhshanrad N, Khan ZH, Sa-beri H. Recombinant Activated Factor VII, as a Remedy for Intractable Coagulopathy Following Massive Transfusion in a Case of Giant Cranial Neurofbroma. Arch Neurosci. 2014;2(2).